Precigen is trading 5.02% up at $8.09 after B. Riley initiated coverage on September 25, 2026, with a Buy rating and a $12 price target. - The target implies approximately 56% upside from the prior close of $7.70. - The analyst highlighted PAPZIMEOS and Precigen’s commercial-stage immuno-oncology profile. - The broader market is also firmer, but the initiation is the clearest company-specific catalyst.